These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 28382381)
21. Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab. Dittrich D; Pyka T; Scheidhauer K; Lütje S; Essler M; Bundschuh RA Nuklearmedizin; 2020 Jun; 59(3):228-234. PubMed ID: 32259852 [TBL] [Abstract][Full Text] [Related]
22. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022 [TBL] [Abstract][Full Text] [Related]
23. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients. Schiza A; Irenaeus S; Ortiz-Nieto F; Loskog A; Tötterman T; Sundin A; Ullenhag GJ; Ahlström H Sci Rep; 2019 Dec; 9(1):18069. PubMed ID: 31792256 [TBL] [Abstract][Full Text] [Related]
25. The prognostic value of [ Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131 [TBL] [Abstract][Full Text] [Related]
27. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228 [TBL] [Abstract][Full Text] [Related]
28. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374 [TBL] [Abstract][Full Text] [Related]
29. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Dimitrakopoulou-Strauss A Cancer Immunol Immunother; 2019 May; 68(5):813-822. PubMed ID: 30123922 [TBL] [Abstract][Full Text] [Related]
30. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma. Twycross SH; Burger H; Holness J S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864 [TBL] [Abstract][Full Text] [Related]
32. FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Engell-Noerregaard L; Hendel HW; Johannesen HH; Alslev L; Svane IM Cancer Immunol Immunother; 2013 Jan; 62(1):17-25. PubMed ID: 22722450 [TBL] [Abstract][Full Text] [Related]
33. Clinical significance of signs of autoimmune colitis in Lang N; Dick J; Slynko A; Schulz C; Dimitrakopoulou-Strauss A; Sachpekidis C; Enk AH; Hassel JC Immunotherapy; 2019 Jun; 11(8):667-676. PubMed ID: 31088239 [No Abstract] [Full Text] [Related]
34. Fluorodeoxyglucose-PET in the management of malignant melanoma. Kumar R; Mavi A; Bural G; Alavi A Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645 [TBL] [Abstract][Full Text] [Related]